Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:36:15.086Z.
Calculation as of: 2026-10-06T15:36:15.086Z.
Quote observation: 2026-10-06T15:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26be04fabca1f5abb96b6b094ab833c4d2e2f23bc88365d6eea621c26c981704
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Corbus Pharmaceuticals Holdings, Inc.
Market Cap
$108.57M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.80M
EBITDA Yield
N/A
TTM Avg
5.35%
3Y Avg
4.92%
5Y Avg
4.17%
Market Cap
$110.31M
EBITDA Yield
N/A
TTM Avg
6.77%
3Y Avg
6.77%
5Y Avg
6.77%
Market Cap
$110.95M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.31M
EBITDA Yield
204.02%
TTM Avg
162.58%
3Y Avg
142.94%
5Y Avg
38.81%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $108.57M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $108.32M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.80M | N/A | 5.35% | 4.92% | 4.17% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.64M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $110.31M | N/A | 6.77% | 6.77% | 6.77% |
| Immunic, Inc. (IMUX)vs › | $110.43M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $116.34M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.95M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.31M | 204.02% | 162.58% | 142.94% | 38.81% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
